go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

International Medication Systems (UK) Ltd

International Medication Systems (UK) Ltd
208 Bath Road, Slough, Berkshire, SL1 3WE, UK
Telephone: +44 (0)1753 534 655
Medical Information Direct Line: +44 (0)1753 447 690
Medical Information e-mail: medicalinformationuk@ucb.com
Customer Care direct line: +44 (0)800 953 0183
Medical Information Facsimile: +44 (0)1753 447 690


Summary of Product Characteristics last updated on medicines.ie: 24/09/2008
SPC Glucose Injection (Minijet)

Table of Contents

  • 1. NAME OF THE MEDICINAL PRODUCT
  • 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
  • 3. PHARMACEUTICAL FORM
  • 4. CLINICAL PARTICULARS
  • 4.1 Therapeutic indications
  • 4.2 Posology and method of administration
  • 4.3 Contraindications
  • 4.4 Special warnings and precautions for use
  • 4.5 Interaction with other medicinal products and other forms of interaction
  • 4.6 Pregnancy and lactation
  • 4.7 Effects on ability to drive and use machines
  • 4.8 Undesirable effects
  • 4.9 Overdose
  • 5. PHARMACOLOGICAL PROPERTIES
  • 5.1 Pharmacodynamic properties
  • 5.2 Pharmacokinetic properties
  • 5.3 Preclinical safety data
  • 6. PHARMACEUTICAL PARTICULARS
  • 6.1 List of excipient(s)
  • 6.2 Incompatibilities
  • 6.3 Shelf life
  • 6.4 Special precautions for storage
  • 6.5 Nature and contents of container
  • 6.6 Special precautions for disposal and other handling
  • 7. MARKETING AUTHORISATION HOLDER
  • 8. MARKETING AUTHORISATION NUMBER(S)
  • 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
  • 10. DATE OF REVISION OF THE TEXT


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Glucose Injection BP Minijet 50% w/v, solution for injection.


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Glucose anhydrous 500mg in 1ml as 5g/10ml or 25g/50ml.

For a full list of excipients, see section 6.1


Go to top of the page
3. PHARMACEUTICAL FORM

Solution for injection.

The clear, colourless solution is contained in a type 1 glass vial with an elastomeric closure. The container is specially designed for use with the IMS Minijet injector supplied.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

a) As a source of energy in parenteral nutrition.

b) In severe hypoglycaemia due to insulin excess or other causes.

c) For the treatment of delirium tremens or acute alcohol intoxication.

Glucose injection 50% w/v is strongly hypertonic and is used partly because of its dehydrating effects. In delerium tremens or acute alcohol intoxication the patient must be rehydrated


Go to top of the page
4.2 Posology and method of administration

Hypertonic solutions of glucose should be administered via a central vein. The dose is variable and depends upon the indication, clinical condition and size of the individual.

The rate of utilisation of glucose varies considerably from patient to patient. In general, the maximal rate has been estimated at 500-800mg/kg body weight/hour. If the patient's capacity to utilise glucose is exceeded, glycosuria and diuresis will occur.

Adults, elderly, children over 6 years:

Hypoglycaemia: 20-50ml of a 50% w/v solution, repeated as necessary according to the patient's response, by slow intravenous injection, e.g. 3ml/minute. After 25g of glucose has been given, it is advisable to interrupt the injection and evaluate the effect. The exact dose required to relieve hypoglycaemia will vary. After the patient responds, supplemental oral feeding is indicated to avoid relapse, especially after insulin shock therapy.

Acute alcoholism: 50ml of glucose 50% w/v solution should be administered intravenously. Unmodified insulin (20 units) and thiamine hydrochloride (100mg) should be added to the infusion. Blood sugar should be measured frequently until stable.


Go to top of the page
4.3 Contraindications

The intravenous use of strongly hypertonic solutions of glucose is contraindicated in patients with anuria, intracranial or intraspinal haemorrhage, or delirium tremens if the patient is already dehydrated.

Known sensitivity to corn or corn products, hyperglycaemic coma, or ischaemic stroke.


Go to top of the page
4.4 Special warnings and precautions for use

Hypertonic solutions of glucose should be administered via a large central vein to minimise the damage at the site of injection.

Use with caution in patients with diabetes mellitus, severe undernutrition, carbohydrate intolerance, thiamine deficiency, hypophosphataemia, haemodilution, sepsis and trauma. Rapid infusion of hypertonic glucose solution may lead to hyperglycaemia. Patients should be observed for signs of mental confusion or loss of consciousness.

Prolonged use in parenteral nutrition may affect insulin production; blood and urine glucose should be monitored. Fluid and acid-base balance and electrolyte status should also be determined during therapy with dextrose.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known.


Go to top of the page
4.6 Pregnancy and lactation

Intravenous glucose may result in considerable foetal insulin production, with an associated risk of rebound hypoglycaemia in the new-born. Infusion should not exceed 5-10g/hour during labour or Caesarean section.


Go to top of the page
4.7 Effects on ability to drive and use machines

This preparation is intended for use only in emergencies.


Go to top of the page
4.8 Undesirable effects

Anaphylactoid reactions have been reported in patients with asthma and diabetes mellitus.

Local pain, inflammation, irritation, thrombophlebitis and fever may occur.

Hypokalaemia, hypomagnesaemia or hypophosphataemia may result from the use of hypertonic solutions via the intravenous route.

Prolonged or rapid administration of hyperosmotic >5%) solutions may lead to dehydration.

The administration of glucose without adequate levels of thiamine (which form the coenzyme systems in its metabolism), may precipitate overt deficiency states, e.g. Wernicke's encephalopathy.

Excess glucose infusion produces increased CO2, which may be important in respiratory failure, and stimulates catecholamine secretion.


Go to top of the page
4.9 Overdose

The patient becomes hyperglycaemic and glycosuria may occur. This can lead to dehydration, hyperosmolar coma and death.

Treatment: The infusion should be discontinued and the patient evaluated. Insulin may be administered and appropriate supportive measures taken.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Glucose, the natural sugar occurring in the blood, is the principle source of energy for the body. It is readily converted to fat and is also stored in the liver and muscles as glycogen. When a rapid rise in blood sugar is demanded by the body, glycogen is quickly liberated as d-glucose. When the supply of glucose is insufficient, the body mobilises fat stores which are converted to acetate with production of energy by the same oxidative pathways employed in the combustion of glucose.

It may decrease body protein and nitrogen losses. Glucose is also the probable source of glucuronic acid with which many foreign substances and their metabolites combine to form excretion products. It probably provides the basic substances required for the formation of hyalluronates and chondroitin sulphates, the supporting structures of the organism. It can be converted to a pentose essential for the formation of nucleic acids by the cells.


Go to top of the page
5.2 Pharmacokinetic properties

Glucose is metabolised to carbon dioxide and water with the release of energy.


Go to top of the page
5.3 Preclinical safety data

Not applicable since glucose has been used in clinical practice for many years and its effects in man are well known.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipient(s)

Water for Injections


Go to top of the page
6.2 Incompatibilities

Glucose solutions which do not contain electrolytes should not be administered concomitantly with blood through the same infusion set as haemolysis and clumping may occur. This medicinal product must not be mixed with other medicinal products except those mentioned in section 4.2.


Go to top of the page
6.3 Shelf life

Unopened: 3 years

Once open: Use immediately. Discard any unused portion.


Go to top of the page
6.4 Special precautions for storage

Store below 25°C.


Go to top of the page
6.5 Nature and contents of container

The solution is contained in a type I glass vial with an elastomeric closure which meets all the relevant specifications. The product is available as 10 ml and 50ml.


Go to top of the page
6.6 Special precautions for disposal and other handling

The container is specially designed for use with the IMS Minijet injector. Do not use the injection if crystals have separated. For single use only. Discard any remaining contents after use.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

International Medication Systems (UK) Ltd

208 Bath Road

Slough

Berkshire

SL1 3EW

UK


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PA 255/8/3


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorization: 08 September 1977

Date of last renewal: 08 September 2007


Go to top of the page
10. DATE OF REVISION OF THE TEXT

September 2008

POM



Link to this document from your website:
http://www.medicines.ie/medicine/4640/SPC/Glucose+Injection+(Minijet)/

Document Links

 
  Link to this page
  View all medicines
from this company
Print this page
View document history
Bookmark and Share

Active Ingredients

 
   Glucose anhydrous

  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo